Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study

作者：Jian Zhang, Ruifeng Liu, Shixuan Wang, Zhe Feng, Huazhe Yang, Shan Gao, X Li, Xueqing Yao, Jie Chen, Z. Gong, Yafei Li, X Li, Shixuan Wang, Caixia Hu, Jingjing Liu, M. Zhang, Fei Yuan, Ben Shi, Hanmei Lou, Peng Zhao, Feng-Fang Qiu, Hanxu Guo, Bo Hu, Danfeng Xu, Huiyi Huang, Xiao Zhang, Mei Feng, Xianlong Wang, Guiling Li, D. Liu, Daniel Chen, Peng Wang · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.04.009 · 被引用次数：27 · 研究领域：Proteoglycans and glycosaminoglycans research、HER2/EGFR in Cancer Research、Toxin Mechanisms and Immunotoxins